Axsome Therapeutics, Inc.
General ticker "AXSM" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $5.5B (TTM average)
Axsome Therapeutics, Inc. follows the US Stock Market performance with the rate: 41.6%.
Estimated limits based on current volatility of 1.5%: low 145.14$, high 149.71$
Factors to consider:
- Total employees count: 683 as of 2024
- US accounted for 98.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Significant losses, Profitability concerns, Internal control weaknesses, Dependence on key products, Regulatory and compliance
- Current price 34.3% above estimated high
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [46.76$, 110.19$]
- 2025-12-31 to 2026-12-31 estimated range: [39.97$, 96.07$]
Financial Metrics affecting the AXSM estimates:
- Negative: with PPE of -18.9 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.06 <= 0.33
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.01 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of -1.38 <= -0.75
Short-term AXSM quotes
Long-term AXSM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $50.04MM | $270.60MM | $385.69MM |
| Operating Expenses | $229.84MM | $502.43MM | $666.25MM |
| Operating Income | $-179.80MM | $-231.82MM | $-280.56MM |
| Non-Operating Income | $-7.33MM | $-6.45MM | $-6.57MM |
| R&D Expense | $57.95MM | $97.94MM | $187.08MM |
| Income(Loss) | $-187.13MM | $-238.28MM | $-287.13MM |
| Taxes | $0.00MM | $0.96MM | $0.09MM |
| Profit(Loss)* | $-187.13MM | $-239.24MM | $-287.22MM |
| Stockholders Equity | $109.56MM | $190.98MM | $57.02MM |
| Inventory | $4.32MM | $15.13MM | $15.73MM |
| Assets | $331.48MM | $588.24MM | $568.50MM |
| Operating Cash Flow | $-116.51MM | $-145.08MM | $-128.41MM |
| Capital expenditure | $0.70MM | $0.58MM | $0.27MM |
| Investing Cash Flow | $-53.70MM | $-0.58MM | $-0.27MM |
| Financing Cash Flow | $284.58MM | $331.01MM | $57.84MM |
| Earnings Per Share** | $-4.60 | $-5.27 | $-5.99 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.